Application of artesunate in preparation of medicines for treating infantile hemangioma

A technology of artesunate and hemangioma, applied in the field of medicine, can solve problems such as limited penetration depth, difficulty in evaluating long-term side effects, and inability to effectively control the growth of hemangioma

Inactive Publication Date: 2013-12-25
CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] There are many means of clinical treatment of hemangioma in children. The current status and shortcomings of hemangioma treatment, such as 1. Hormone therapy: including oral administration and local injection, can achieve exact results. Disadvantages: ① induce or aggravate local infection ② substance metabolism and water-salt Metabolic disorders Long-term use of glucocorticoids in large quantities can cause substance metabolism and water-salt metabolism disorders, adrenal hyperfunction syndrome, ③ cardiovascular system complications, long-term use of glucocorticoids, because it can lead to sodium, water retention and blood lipids High, can induce hypertension and atherosclerosis
2. The exact mechanism of propranolol oral treatment is not yet clear
Disadvantages: During the treatment process, it is necessary to closely observe the changes in the heart function and blood sugar of the child, and the drug should be discontinued if the following points occur: ① Bradycardia or heart rate drops below 70% of the heart rate value in the awake state of children of the same age; ② Hypotension symptoms or blood pressure drop The blood pressure value is more than 25% higher than that of children of the same age in awake state; ③ hypoglycemia symptoms; ④ wheezing or dyspnea
[0004] Disadvantages of sclerosing agent injection therapy: severe pain dur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] Describe technical content of the present invention in detail below by embodiment:

[0011] Artesunate injection preparation: 10mg artesunate+0.6mlNaHCO3+5.4m10.9%NaCl, set up control group, artesunate final concentration 100ug / ml, 200ug / ml, 300ug / ml, 400ug / ml, 500ug / ml concentration group

[0012] 1. Cell experiments:

[0013] ① MTT method was used to detect the inhibitory effect of artesunate in different concentration groups on the proliferation of EOMA cells for 24 hours, 48 ​​hours and 72 hours;

[0014] ② Cell migration inhibition experiment: Transwell kit was used to detect the inhibitory effect of artesunate in different concentration groups on EOMA cells for 28 hours;

[0015] ③Flow cytometry was used to measure the effect of different concentrations of artesunate on the cell cycle of EOMA cells at 24 hours, 48 ​​hours and 72 hours;

[0016] ④ RT-PCR to detect the effect of artesunate in different concentration groups on the gene level of EOMA cells at 24 ho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of artesunate in the preparation of medicines for treating infantile hemangioma. The medicines can fundamentally treat the hemangioma from the pathogenesis against hemangioma forming pathologic mechanisms, have small side effects, do not cause local embolism or severe necrosis of normal tissues, and can obviously reduce the clinic treatment cost because of the low price of the artesunate.

Description

Technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of artesunate in the preparation of medicines for treating infantile hemangiomas. Background technique [0002] Hemangioma is a common congenital abnormality of vascular development in infants and young children. The incidence of hemangioma in infants and young children is 10%-12%. The incidence rate is high. Currently, there are various clinical treatment methods. In the study of infantile hemangioma, Dan xu et al. found that SALL4+ and CD133 were highly expressed in hemangioma cells in the proliferating phase than in the hemangioma cells in the regressing phase, confirming that hemangiomas have stem cell characteristics. Damian Medici found in the research on the mechanism of rapamycin in the treatment of proliferative hemangioma that rapamycin can inhibit the proliferation of vascular endothelial cells by inhibiting the mTOR pathway and reducing the expressi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/357A61K9/08A61P35/00A61P9/00
Inventor 金先庆赵占波王宁金鑫丁雄辉
Owner CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products